Vanillin Affects Amyloid Aggregation and Non-Enzymatic Glycation in Human Insulin

[1]  R. Simó,et al.  Cognitive impairment and dementia: a new emerging complication of type 2 diabetes—The diabetologist’s perspective , 2017, Acta Diabetologica.

[2]  D. Mcclements,et al.  Physical and Chemical Stability of Curcumin in Aqueous Solutions and Emulsions: Impact of pH, Temperature, and Molecular Environment. , 2017, Journal of agricultural and food chemistry.

[3]  A. Saremi,et al.  Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study , 2017, Diabetes Care.

[4]  G. Reddy,et al.  Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy , 2016, Biomolecular concepts.

[5]  G. Manco,et al.  Glycation in Demetalated Superoxide Dismutase 1 Prevents Amyloid Aggregation and Produces Cytotoxic Ages Adducts , 2016, Front. Mol. Biosci..

[6]  T. Nakazawa,et al.  The relationship between advanced glycation end products and ocular circulation in type 2 diabetes. , 2016, Journal of diabetes and its complications.

[7]  Saurabh Awasthi,et al.  Vanillin restrains non-enzymatic glycation and aggregation of albumin by chemical chaperone like function. , 2016, International journal of biological macromolecules.

[8]  T. Manivasagam,et al.  Vanillin Attenuated Behavioural Impairments, Neurochemical Deficts, Oxidative Stress and Apoptosis Against Rotenone Induced Rat Model of Parkinson’s Disease , 2016, Neurochemical Research.

[9]  T. Asakura,et al.  Characterization of Novel Insulin Fibrils That Show Strong Cytotoxicity Under Physiological pH. , 2016, Journal of pharmaceutical sciences.

[10]  W. Hennink,et al.  A Kinetic Degradation Study of Curcumin in Its Free Form and Loaded in Polymeric Micelles , 2016, The AAPS Journal.

[11]  Liang Shen,et al.  How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies , 2016, Scientific Reports.

[12]  Maotian Xu,et al.  Studies on the interaction between vanillin and β-Amyloid protein via fluorescence spectroscopy and atomic force microscopy , 2016, Chemical Research in Chinese Universities.

[13]  S. Jett,et al.  Curcumin Attenuates Amyloid-β Aggregate Toxicity and Modulates Amyloid-β Aggregation Pathway. , 2016, ACS chemical neuroscience.

[14]  C. Fierke,et al.  Influence of a curcumin derivative on hIAPP aggregation in the absence and presence of lipid membranes. , 2016, Chemical communications.

[15]  Xiao-Bin Jia,et al.  Curcumin inhibits advanced glycation end product-induced oxidative stress and inflammatory responses in endothelial cell damage via trapping methylglyoxal , 2015, Molecular medicine reports.

[16]  S. Nabavi,et al.  Curcumin: a natural product for diabetes and its complications. , 2015, Current topics in medicinal chemistry.

[17]  L. Altucci,et al.  Glycation of Wild‐Type Apomyoglobin Induces Formation of Highly Cytotoxic Oligomeric Species , 2015, Journal of cellular physiology.

[18]  S. Yamagishi,et al.  Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes , 2015, Molecular medicine.

[19]  P. Palumaa,et al.  Insulin Fibrillization at Acidic and Physiological pH Values is Controlled by Different Molecular Mechanisms , 2015, The Protein Journal.

[20]  R. Winter,et al.  pH-Driven Polymorphism of Insulin Amyloid-Like Fibrils , 2015, PloS one.

[21]  M. Choudhary,et al.  Glycation, carbonyl stress and AGEs inhibitors: a patent review , 2015, Expert opinion on therapeutic patents.

[22]  A. Surolia,et al.  Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α-Synuclein , 2015, Scientific Reports.

[23]  C. Schalkwijk.  Vascular AGE-ing by methylglyoxal: the past, the present and the future , 2015, Diabetologia.

[24]  P. B. Luis,et al.  Degradation of Curcumin: From Mechanism to Biological Implications. , 2015, Journal of agricultural and food chemistry.

[25]  Tobias Jung,et al.  Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus , 2015, Biomolecules.

[26]  Satomi Ise,et al.  Structure activity relationship study of curcumin analogues toward the amyloid-beta aggregation inhibitor. , 2014, Bioorganic & medicinal chemistry letters.

[27]  G. Schneider,et al.  Vanillin-derived antiproliferative compounds influence Plk1 activity. , 2014, Bioorganic & medicinal chemistry letters.

[28]  Suresh Govindaraghavan,et al.  Natural compounds and plant extracts as therapeutics against chronic inflammation in Alzheimer's disease--a translational perspective. , 2014, CNS & neurological disorders drug targets.

[29]  Liang Shen,et al.  Can improving bioavailability improve the bioactivity of curcumin? , 2014, Trends in pharmacological sciences.

[30]  A. Dogan,et al.  Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[31]  K. Iwaya,et al.  Insulin-derived amyloidosis and poor glycemic control: a case series. , 2014, The American journal of medicine.

[32]  Liang Shen,et al.  The multiple pharmaceutical potential of curcumin in Parkinson's disease. , 2014, CNS & neurological disorders drug targets.

[33]  Nirmal Singh,et al.  Advanced Glycation End Products and Diabetic Complications , 2014, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.

[34]  Y. Hayashino,et al.  Localized Amyloidosis at the Site of Repeated Insulin Injection in a Patient With Type 2 Diabetes , 2013, Diabetes Care.

[35]  F. Ampudia-Blasco,et al.  Stability and Performance of Rapid-Acting Insulin Analogs Used for Continuous Subcutaneous Insulin Infusion: A Systematic Review , 2013, Journal of diabetes science and technology.

[36]  K. Pallauf,et al.  Neuroprotective properties of curcumin in Alzheimer's disease--merits and limitations. , 2013, Current medicinal chemistry.

[37]  Atefeh Rabiee,et al.  How curcumin affords effective protection against amyloid fibrillation in insulin. , 2013, Food & function.

[38]  R. Mason,et al.  Curcumin and its Derivatives: Their Application in Neuropharmacology and Neuroscience in the 21st Century , 2013, Current neuropharmacology.

[39]  A. Moosavi-Movahedi,et al.  Structural Analysis and Aggregation Propensity of Reduced and Nonreduced Glycated Insulin Adducts , 2013, Applied Biochemistry and Biotechnology.

[40]  O. Galzitskaya,et al.  Structural polymorphism and possible pathways of amyloid fibril formation on the example of insulin protein , 2012, Biochemistry (Moscow).

[41]  M. Fändrich,et al.  Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. , 2012, Journal of molecular biology.

[42]  C. Chyau,et al.  Trapping of methylglyoxal by curcumin in cell-free systems and in human umbilical vein endothelial cells. , 2012, Journal of agricultural and food chemistry.

[43]  Chun Wu,et al.  Binding of Congo red to amyloid protofibrils of the Alzheimer Aβ(9-40) peptide probed by molecular dynamics simulations. , 2012, Biophysical journal.

[44]  H. Fetoui,et al.  Protective effect of vanillin against carbon tetrachloride (CCl4)-induced oxidative brain injury in rats , 2012, Toxicology and industrial health.

[45]  Liang Shen,et al.  Low stability remedies the low bioavailability of curcumin , 2012 .

[46]  Samuel Sparks,et al.  Curcumin modulates the self-assembly of the islet amyloid polypeptide by disassembling α-helix. , 2012, Biochemical and biophysical research communications.

[47]  Zhongling Zhang,et al.  Advanced glycation end products and neurodegenerative diseases: Mechanisms and perspective , 2012, Journal of the Neurological Sciences.

[48]  V. Fogliano,et al.  Curcumin bioavailability from enriched bread: the effect of microencapsulated ingredients. , 2012, Journal of agricultural and food chemistry.

[49]  Liang Shen,et al.  The pharmacology of curcumin: is it the degradation products? , 2012, Trends in molecular medicine.

[50]  N. Zeghal,et al.  Evaluation of the antioxidant, anti-inflammatory and hepatoprotective properties of vanillin in carbon tetrachloride-treated rats. , 2011, European journal of pharmacology.

[51]  A. Coelho,et al.  Insulin glycation by methylglyoxal results in native-like aggregation and inhibition of fibril formation , 2011, BMC Biochemistry.

[52]  N. Škalko-Basnet,et al.  Curcumin: An Anti-Inflammatory Molecule from a Curry Spice on the Path to Cancer Treatment , 2011, Molecules.

[53]  C. Schalkwijk,et al.  Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics , 2010, Amino Acids.

[54]  M. Biancalana,et al.  Molecular mechanism of Thioflavin-T binding to amyloid fibrils. , 2010, Biochimica et biophysica acta.

[55]  Mong-Hong Lee,et al.  The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth , 2010, Journal of cellular and molecular medicine.

[56]  T. Outeiro,et al.  The sour side of neurodegenerative disorders: the effects of protein glycation , 2010, The Journal of pathology.

[57]  David Eisenberg,et al.  Molecular basis for insulin fibril assembly , 2009, Proceedings of the National Academy of Sciences.

[58]  Liang Shen,et al.  Contribution of Degradation Products to the Anticancer Activity of Curcumin , 2009, Clinical Cancer Research.

[59]  A. Nègre-Salvayre,et al.  Hyperglycemia and glycation in diabetic complications. , 2009, Antioxidants & redox signaling.

[60]  Tak W. Kee,et al.  The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds , 2009, The FEBS journal.

[61]  Kuan-Nan Liu,et al.  Effect of curcumin on the amyloid fibrillogenesis of hen egg-white lysozyme. , 2009, Biophysical chemistry.

[62]  C. Roberts,et al.  Insulin fibril nucleation: the role of prefibrillar aggregates. , 2008, Biophysical journal.

[63]  L. Serpell,et al.  Amyloid fibrils , 2008, Prion.

[64]  William C. Nolan,et al.  Curcumin inhibits aggregation of α-synuclein , 2008, Acta Neuropathologica.

[65]  Robert A Newman,et al.  Bioavailability of curcumin: problems and promises. , 2007, Molecular pharmaceutics.

[66]  G. McRae,et al.  A three-stage kinetic model of amyloid fibrillation. , 2007, Biophysical journal.

[67]  Dmitri I Svergun,et al.  A Helical Structural Nucleus Is the Primary Elongating Unit of Insulin Amyloid Fibrils , 2007, PLoS biology.

[68]  F. Khand,et al.  Liquid Chromatographic Determination of Glyoxal and Methylglyoxal from Serum of Diabetic Patients using Meso‐Stilbenediamine as Derivatizing Reagent , 2006 .

[69]  A. Fink,et al.  Fibrillation of human insulin A and B chains. , 2006, Biochemistry.

[70]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[71]  V. Uversky,et al.  Early Events in the Fibrillation of Monomeric Insulin* , 2005, Journal of Biological Chemistry.

[72]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[73]  C. Richards,et al.  Examination of insulin injection sites: an unexpected finding of localized amyloidosis , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[74]  K. Sainis,et al.  Free radical scavenging activity of vanillin and o-vanillin using 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical , 2002, Redox report : communications in free radical research.

[75]  S. Jee,et al.  Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. , 2001, Anticancer research.

[76]  V. Uversky,et al.  Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. , 2001, Biochemistry.

[77]  H. McNulty,et al.  Impaired ability of glycated insulin to regulate plasma glucose and stimulate glucose transport and metabolism in mouse abdominal muscle. , 2000, Biochimica et biophysica acta.

[78]  C. Dobson,et al.  Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry. , 2000, Biophysical journal.

[79]  T. Osawa,et al.  Methylglyoxal Modification of Protein , 1999, The Journal of Biological Chemistry.

[80]  H. Hammes,et al.  Differential accumulation of advanced glycation end products in the course of diabetic retinopathy , 1999, Diabetologia.

[81]  D. Steiner,et al.  The role of assembly in insulin's biosynthesis. , 1998, Current opinion in structural biology.

[82]  P. Flatt,et al.  Glycation of insulin results in reduced biological activity in mice , 1997, Acta Diabetologica.

[83]  Jen-kun Lin,et al.  Stability of curcumin in buffer solutions and characterization of its degradation products. , 1997, Journal of pharmaceutical and biomedical analysis.

[84]  P. Flatt,et al.  Glycation of Insulin in the Islets of Langerhans of Normal and Diabetic Animals , 1996, Diabetes.

[85]  L. Altucci,et al.  D-ribose-glycation of insulin prevents amyloid aggregation and produces cytotoxic adducts. , 2016, Biochimica et biophysica acta.

[86]  Y. Gupta,et al.  Insulin-derived amyloidosis , 2015, Indian journal of endocrinology and metabolism.

[87]  R. Wada,et al.  Localized amyloidosis at the site of repeated insulin injection in a diabetic patient. , 2010, Internal medicine.

[88]  B. Aggarwal,et al.  Curcumin: the Indian solid gold. , 2007, Advances in experimental medicine and biology.

[89]  C M Dobson,et al.  Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy , 2000, Protein science : a publication of the Protein Society.